Paper Details

  1. Home
  2. Paper Details

Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.

Author: AarslandD, BallardC, BroadstockM, RongveA, SvenningssonP

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Dementia is common in people with Parkinson's disease (PDD) and dementia with Lewy bodies (DLB) but there are few effective treatments. Studies show that rivastigmine can help improve thinking and functioning in both conditions, and may also reduce falls in PDD. Memantine shows promise, particularly for PDD, but the evidence is mixed. It may also improve movement problems and involuntary movements in PD. While there's limited research on treating cognitive decline in PD without dementia, there is some early evidence for atomoxetine, memantine, and piribedil. More research is needed on treating hallucinations and depression in PDD and DLB. Scientists are also investigating if medications can prevent or slow dementia progression in people with PD.
Paper Details　
Original Abstract of the Article :
Despite the frequency and importance of dementia associated with Parkinson's disease (PDD) and dementia with Lewy bodies (DLB), there is relatively little evidence on which to base treatment. Evidence from meta-analysis suggests that rivastigmine can improve cognition and functioning in PDD and also...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11910-012-0290-7

データ提供：米国国立医学図書館（NLM）

Dementia with Lewy Bodies and Parkinson's Disease Dementia: A Review of Treatment Options

Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are neurodegenerative disorders that affect cognition, movement, and behavior. Finding effective treatments for these conditions remains a significant challenge. This review article, published in [Journal Name], examines the current state of clinical trials for DLB and PDD, summarizing the available evidence for various treatment approaches.

Exploring Treatment Options for DLB and PDD: A Review of Clinical Trials

The authors highlight the limited evidence base for treatment, emphasizing the need for further research. They summarize the findings of meta-analyses, suggesting that rivastigmine may be effective in improving cognition and functioning in both DLB and PDD, as well as reducing the risk of falls. Memantine is also discussed as a potential treatment option, particularly for PDD, although the evidence is more conflicting. The review also discusses the lack of systematic evidence for the treatment of visual hallucinations and depression in DLB and PDD, underscoring the need for more research in these areas.

Navigating the Desert of Neurodegenerative Disorders: Seeking Effective Treatments

Imagine a vast desert of the mind, where memories and thoughts are like shimmering oases, susceptible to the encroaching sands of neurodegeneration. DLB and PDD are like sandstorms that erode these oases, impacting cognition and overall well-being. This review provides a roadmap through this challenging landscape, exploring various treatment options and highlighting the need for ongoing research to develop effective therapies.

Dr.Camel's Conclusion

This review emphasizes the critical need for further research to develop effective treatments for dementia with Lewy bodies and Parkinson's disease dementia. It's a reminder that in the vast desert of neurodegenerative disorders, we must continue to search for oases of hope and progress, seeking solutions that can improve the lives of patients and their families.

Date :
  1. Date Completed 2013-04-03
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22806065

DOI: Digital Object Identifier

10.1007/s11910-012-0290-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.